KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor-Positive/HER2-/PIK3CA Wild-Type Advanced Breast Cancer.

Sara A Hurvitz, Rachel M Layman, Giuseppe Curigliano, Fabrice André, Massimo Cristofanilli, Sung-Bae Kim, Jorge Luis Martínez Rodríguez, Jorge C Nadal, Gun Min Kim, Louisa Lo, Yuly A Remolina-Bonilla, Geronimo Rosselli, George Emile, Ernesto Korbenfeld, Juan Manuel Puig, Robert Wesolowski, Miguel Martin, Alistair Ring, Hyo S Han, Antonio Giordano, Sarah C Mutka, Keren Moss, Sam Suzuki, Brian Sullivan, Igor Gorbatchevsky, Barbara Pistilli, VIKTORIA-1 Study Group

J Clin Oncol 44(12) 1108-1119

PMID41802242
PMCIDPMC13075786
DOI10.1200/JCO-25-02643
发表日期2026-03-09
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 4 张 PMC Figure,均未识别为 KM 图:FIG 1.:非 KM 图;FIG 2.:AI 判定为 multi panel km;FIG 3.:森林图/亚组分析图;FIG 4.:AI 判定为 multi panel km。
摘要

摘要

PURPOSE: Gedatolisib potently targets all four class I PI3K isoforms and mTORC1 and mTORC2 to comprehensively block the PI3K/AKT/mTOR pathway and has shown compelling activity in early clinical trials with palbociclib and fulvestrant. METHODS: This phase III randomized trial (VIKTORIA-1; ClinicalTrials.gov identifier: NCT05501886) evaluated the efficacy of gedatolisib-based therapy, comparing gedatolisib, palbociclib, and fulvestrant (gedatolisib triplet) and gedatolisib plus fulvestrant (gedatolisib doublet) with fulvestrant monotherapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HER2-), PIK3CA wild-type (WT) advanced breast cancer. Eligible patients had disease progression during or after CDK4/6 inhibitor and aromatase inhibitor treatment. Comparison of progression-free survival as assessed by blinded independent central review for gedatolisib triplet versus fulvestrant and gedatolisib doublet versus fulvestrant was the primary objective. RESULTS: A total of 392 patients were randomly assigned 1:1:1. The median study follow-up was 10.1 months. The median progression-free survival was 9.3 months in the gedatolisib-triplet group, 2.0 months in the fulvestrant group (hazard ratio [HR] for progression or death, 0.24 [95% CI, 0.17 to 0.35]; P < .001), and 7.4 months in the gedatolisib-doublet group (HR, 0.33 [95% CI, 0.24 to 0.48]; P < .001 v fulvestrant). Grade ≥3 treatment-related adverse events (TRAEs) reported in the gedatolisib-triplet and gedatolisib-doublet groups, respectively, included neutropenia (62.3%, 0.8%), stomatitis (19.2%, 12.3%), rash (4.6%, 5.4%), hyperglycemia (2.3%, 2.3%), and diarrhea (1.5%, 0.8%). Study treatment discontinuation because of TRAEs was reported in 2.3% (triplet) and 3.1% (doublet) of patients. CONCLUSION: The addition of gedatolisib to fulvestrant, with or without palbociclib, significantly reduced the risk of disease progression or death in patients with hormone receptor-positive/HER2-, PIK3CA WT advanced breast cancer.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

FIG 2.

PFS. Kaplan-Meier estimates of progression-free survival are shown for patients randomly assigned to (A) gedatolisib plus palbociclib and fulvestrant versus fulvestrant alone and (B) gedatolisib plus fulvestrant versus fulvestrant alone. mPFS, median progression-free survival; PFS, progression-free survival.

A

PFS

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示曲线 1:short span
查看结果
B

PFS

FIG 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

FIG 4.

OS (interim analysis). Kaplan-Meier estimates of OS are shown for patients randomly assigned to (A) gedatolisib plus palbociclib and fulvestrant versus fulvestrant alone and (B) gedatolisib plus fulvestrant versus fulvestrant alone. At the time of this interim analysis, 99 patients (25.3%) had died (30 in the gedatolisib-triplet group, 32 in the gedatolisib-doublet group, and 37 in the fulvestrant group). Sixty-three patients assigned to fulvestrant crossed over to gedatolisib plus palbociclib and fulvestrant (n = 52) or gedatolisib plus fulvestrant (n = 11). Analysis was performed on the intent-to-treat population. The interim boundary for each comparison in this interim analysis was a one-sided alpha of ≤0.00017 to maintain the overall type I error rate of ≤0.025 in the final analysis. Tick marks indicate censored data. mOS, median overall survival; NE, not estimable; NR, not reached; OS, overall survival.

A

OS

FIG 4. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

OS

FIG 4. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 4. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.Patient disposition. The sample size planned for the study was 351 patients (117 in each treatment arm). An additional 41 patients who had given consent and were in active screening at the time the number of events necessary to conduct the primary analysis occurred were allowed to enroll, for a total sample size of 392 patients.
非 KM Figure
FIG 3.Subgroup analysis of PFS. Analyses of PFS across prespecified patient subgroups are shown for patients randomly assigned to (A) gedatolisib plus palbociclib and fulvestrant versus fulvestrant alone and (B) gedatolisib plus fulvestrant versus fulvestrant alone. mPFS, median progression-free survival; PFS, progression-free survival.
非 KM Figure